140 related articles for article (PubMed ID: 17061981)
1. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
[TBL] [Abstract][Full Text] [Related]
2. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
[TBL] [Abstract][Full Text] [Related]
3. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Nichol JL
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
[TBL] [Abstract][Full Text] [Related]
4. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study.
Kumagai Y; Fujita T; Ozaki M; Sahashi K; Ohkura M; Ohtsu T; Arai Y; Sonehara Y; Nichol JL
J Clin Pharmacol; 2007 Dec; 47(12):1489-97. PubMed ID: 17925591
[TBL] [Abstract][Full Text] [Related]
6. Romiplostim: a novel thrombopoiesis-stimulating agent.
Perreault S; Burzynski J
Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
Bussel JB; Kuter DJ; Pullarkat V; Lyons RM; Guo M; Nichol JL
Blood; 2009 Mar; 113(10):2161-71. PubMed ID: 18981291
[TBL] [Abstract][Full Text] [Related]
8. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Nurden AT; Viallard JF; Nurden P
Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
[TBL] [Abstract][Full Text] [Related]
9. Platelet production bolstered with romiplostim approval.
Morrow T
Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
[No Abstract] [Full Text] [Related]
10. Immune thrombocytopenic purpura--the changing therapeutic landscape.
Bromberg ME
N Engl J Med; 2006 Oct; 355(16):1643-5. PubMed ID: 17050888
[No Abstract] [Full Text] [Related]
11. FDA approves thrombopoiesis-stimulating agent.
Thompson CA
Am J Health Syst Pharm; 2008 Oct; 65(19):1788. PubMed ID: 18796411
[No Abstract] [Full Text] [Related]
12. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL
Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.
Wang B; Nichol JL; Sullivan JT
Clin Pharmacol Ther; 2004 Dec; 76(6):628-38. PubMed ID: 15592334
[TBL] [Abstract][Full Text] [Related]
14. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
Mathias SD; Bussel JB; George JN; McMillan R; Okano GJ; Nichol JL
Clin Ther; 2007 May; 29(5):950-962. PubMed ID: 17697914
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
Pullarkat VA; Gernsheimer TB; Wasser JS; Newland A; Guthrie TH; de Wolf JT; Stewart R; Berger D
Am J Hematol; 2009 Aug; 84(8):538-40. PubMed ID: 19569197
[No Abstract] [Full Text] [Related]
16. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim management of immune thrombocytopenic purpura.
Ipema HJ; Jung MY; Lodolce AE
Ann Pharmacother; 2009 May; 43(5):914-9. PubMed ID: 19401474
[TBL] [Abstract][Full Text] [Related]
18. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
Tiu RV; Sekeres MA
Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
[TBL] [Abstract][Full Text] [Related]
20. [Romplostim in the treatment of immune thrombocytopenic purpura at a tertiary hospital].
Riu Viladoms G; Creus Baró N; Estefanell Tejero A; Ribas Sala J
Farm Hosp; 2012; 36(5):434-7. PubMed ID: 22871365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
